Moderna (MRNA) Announced Q4 2025 Earnings on Feb 13 2026, Reporting "Total Revenue was $700 Million"

Moderna reported financial results for the fourth quarter of 2025, stating that "total revenue was $700 million" and the "net loss for the quarter was $800 million". For the full year 2025, "total revenue was $1.9 billion" and "net loss over the year was $2.8 billion". The company "ended the year with $8.1 billion in cash and investments". Management noted that "operating expenses were down $2.2 billion, or 30% over the year".

Business updates highlighted that "mNEXSPIKE captured 24% of the total US retail market" during its launch. The company announced a "5-year strategic agreement with the government of Mexico" and an "agreement with Recordati for the global commercialization of our propionic acidemia". However, executives expressed "disappointment to the FDA refusal to file letter on our flu program, mRNA-1010", noting that "regulatory uncertainty threatens U.S. leadership in innovative medicines".

Looking forward, the company expects "total revenue growth of up to 10% in 2026". Expense guidance anticipates "R&D expenses are anticipated to be approximately $3 billion" and "SG&A expenses are expected to be approximately $1 billion". On the pipeline front, the "phase 3 norovirus program is now fully enrolled", and the "adjuvant melanoma study is one that we are confident will read out this year"